Clinical Policy Title:	testosterone
Policy Number:	RxA.235
Drug(s) Applied:	Testim®, Vogelxo®
Original Policy Date:	03/06/2020
Last Review Date:	04/01/2024
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Hypogonadism (must meet all)**:**

1. Diagnosis of primary hypogonadism or hypogonadotropic hypogonadism;
2. Documentation of serum testosterone level less than the lower end of the normal range of the assay used on at least 2 separate occasions within the last 6 months;
3. Trial and failure of generic testosterone gel, unless contraindicated or clinically significant adverse effects are experienced;

Approval duration

All Lines of Business (except Medicare): 12 months

II. Continued Therapy Approval

A. Hypogonadism:

Member is currently receiving or has been treated with this medication within the past 90 days, excluding manufacturer samples.

Approval duration

All Lines of Business (except Medicare): 12 months

References

1. Basin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744. Available at: https://academic.oup.com/jcem/article/103/5/1715/4939465. Accessed December 29, 2022.

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established	02/2020	03/06/2020
Policy was reviewed: 1. Policy description table updated. 2. Continuation therapy criteria II.A.1. rephrased to "Member is currently receiving medication that has been authorized by RxAdvance or the member has met initial approval criteria listed in this policy"	07/29/2020	09/14/2020

3. Initial therapy and continued therapy approval duration updated. 4. References were updated.		
Policy was reviewed: 1. References were reviewed and updated.	03/31/2021	06/10/2021
Policy was reviewed: 1. References were reviewed and updated.	01/05/2022	04/18/2022
Policy was reviewed: 1. References were reviewed and updated.	12/29/2022	04/13/2023
Policy was reviewed.	10/19/2023	10/19/2023
Policy was reviewed.	4/1/2024	4/1/2024